3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Brain Neoplasms
3
Neoplasms by Site
2
Neoplasms
2
Lymphoma, Large-Cell, Anaplastic
2
Carcinoma, Renal Cell
2
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms by Histologic Type
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Interventions
Docetaxel
6
Radiotherapy
5
Filgrastim
3
Erlotinib Hydrochloride
3
Cetuximab
3
Capecitabine
3
Bevacizumab
3
entrectinib
2
Radiotherapy, Intensity-Modulated
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
Gemcitabine
2
Fluorodeoxyglucose F18
2
Cisplatin
2
Chemotherapy, Adjuvant
2
Acupuncture Therapy
2
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
tanespimycin
1
spartalizumab
1
sargramostim
1
oncogene protein E7, Human papillomavirus type 16
1
entinostat
1
cevimeline
1
alectinib
1
aldesleukin
1
X-Ray Therapy
1
Vorinostat
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
alectinib
×
CNS
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts